NCT03909737View on ClinicalTrials.gov

Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

99,700

Participants

Timeline

Start Date

September 24, 2020

Primary Completion Date

February 1, 2025

Study Completion Date

December 31, 2025

Conditions
Stillbirths and Infant Mortality
Interventions
DRUG

Azithromycin to pregnant women

Azithromycin to pregnant women at antenatal care visits and during delivery

DRUG

Azithromycin to infants

Azithromycin to infants at 6 and 14 week EPI visits

OTHER

Placebo to pregnant women

Placebo to pregnant women at antenatal care visits and during delivery

OTHER

Placebo to infants

Placebo to infants at 6 and 14 week EPI visits

OTHER

No intervention to pregnant women

No intervention to pregnant women

Trial Locations (1)

Unknown

Centre pour le Developpement des Vaccins - Mali, Bamako

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

University of Maryland, Baltimore

OTHER